CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

Please provide your email address to receive an email when new articles are posted on . Global Initiative for Asthma (GINA) guidelines recommend single maintenance and reliever therapy (SMART) for ...

ATS 2024, San Diego – Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen and over 40 percent of academic pulmonary and ...

Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...

Please provide your email address to receive an email when new articles are posted on . For mild to moderate asthma, many providers reported prescribing a 110 µg/actuation fluticasone metered dose ...

“Be wary of [SABA] overuse. It is for when the patient has poor control of their symptoms, but should not be used for routine treatment,” said Holmes, a general practitioner (GP) partner at The Park ...

In patients with chronic obstructive pulmonary disease (COPD), new initiation of beta2-agonist therapy, such as short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), or inhaled ...

Not all asthma is created equal, nor will all therapies work for all patients. With continued innovations in asthma treatments offering new, improved options for patients, we are more prepared than ...

Low number of patients treated based on the Single Maintenance and Reliever Therapy (SMART) guideline. HealthDay News — Only 14.5% of adult patients with moderate or severe asthma are prescribed the ...

AstraZeneca already has its aging two-drug inhaler Symbicort as a maintenance treatment for asthma. Now, with a pair of trial wins, the company looks on track to have a novel doublet for controlling ...